AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00922701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
Study NCT03346798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Photography
Description: Participants will engage in food photography on their smart phones while eating
Study NCT03346798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Food Photography
Description: Participants will engage in non-food photography on their smart phones while eating
Study NCT03346798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Phone Use
Description: Participants will not use their smart phones while eating
Study NCT00969280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized Acupuncture
Description: Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes.
Study NCT00969280 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-acupuncture point shallow penetration acupuncture
Description: Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes.
Study NCT01584570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
Description: ECG monitoring for evaluation of QTc interval
Study NCT01584570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
Description: ECG monitoring for evaluation of QTc interval
Study NCT03963401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
Study NCT03963401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
Study NCT03279471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.
Study NCT03279471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/BIACA
Description: Participants receive 16 weeks of BIACA therapy.
Study NCT03279471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
Study NCT01326325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
Study NCT01326325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Drip continues of NaCl 0,9% in intravenous injection during 4 days
Study NCT03631797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microvascular reactivity evaluation
Description: Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
Study NCT02593045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Study NCT00821327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, Sunitinib
Description: Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity.
Study NCT01809977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: collagen cross-linking procedure (total removal)
Description: patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
Study NCT01809977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: collagen cross-linking procedure (partial removal)
Description: patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
Study NCT04115228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and neuromodulation therapy
Description: The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
Study NCT02703025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GCB-70
Description: green coffee bean extract
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT02646202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Injection of varices
Study NCT02646202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Band ligation
Description: endoscopic banding of varices
Study NCT02646202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scleroligation
Description: intra variceal endoscopic sclerotherapy combined with band ligation.
Study NCT02685592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid nanoemulsion
Description: A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
Study NCT04098640 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: FoundationOne CDx
Description: FoundationOne CDx will be performed using archival tumor tissue
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00303628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT03986268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vit D
Description: The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
Study NCT03986268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit D
Description: The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
Study NCT03632330 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Dexmedetomidine group
Study NCT01811017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser
Study NCT01634711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-C Ligament
Description: The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
Study NCT03632330 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam group
Study NCT03632330 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol group
Study NCT02221895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum follow up appointment 2-3 weeks after delivery
Description: experimental arm
Study NCT02221895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum follow up 6-8wk after delivery
Description: control arm
Study NCT03213015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle dorsiflexion measurement
Description: It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
Study NCT01165346 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fiducials
Description: Implantation of fiducials
Study NCT01165346 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: 3 fractions over 8 to 10 days, 15 Gy/fraction
Study NCT03555578 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin Acetate
Description: Leuprorelin Acetate Injection Kit
Study NCT02689791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4
Description: single dose 26g fiber given at the breakfast meal
Study NCT04274543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
Study NCT04274543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions.
Study NCT03632330 — intervention group
Intervention type: DRUG
Intervention: Midazolam/Propofol
Description: Midazolam/Propofol group
Study NCT02578797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
Study NCT03067415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D565H(Latanoprost 25㎍/㎖)
Description: D565H twice daily
Study NCT03067415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565H(Latanoprost 25㎍/㎖)
Description: D565H twice daily
Study NCT03067415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D565(Latanoprost 50㎍/㎖)
Description: D565 once daily
Study NCT03067415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565(Latanoprost 50㎍/㎖)
Description: D565 once daily
Study NCT02213536 — intervention group
Intervention type: RADIATION
Intervention: VMAT (Volumetric Modulated Arc Therapy)
Description: Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
Study NCT03034928 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 1
Description: Contact lens with investigational coating 1 pre-cycled in OPTI-FREE® RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
Study NCT03034928 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balafilcon A contact lens
Description: Balafilcon A contact lens pre-cycled OPTI-FREE® RepleniSH® MPDS
Study NCT03034928 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OPTI-FREE® RepleniSH® MPDS
Description: Multipurpose contact lens solution
Study NCT03034928 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with investigational coating 2
Description: Contact lens with investigational coating 2 pre-cycled in OPTI-FREE® RepleniSH® MPDS
Study NCT01449032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC
Description: No of cells after culture expansion
Study NCT01449032 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 cc saline
Study NCT00221104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study NCT01810952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
Study NCT01810952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Description: In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
Study NCT01810952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH Insulin
Description: NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
Study NCT04926233 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide + Olodaterol
Description: Tiotropium bromide + Olodaterol
Study NCT04926233 — intervention group
Intervention type: DEVICE
Intervention: Sp(t)iolto® Respimat®
Description: Sp(t)iolto® Respimat®
Study NCT04649307 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MI-CBT
Description: Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
Study NCT03918200 — intervention group
Intervention type: OTHER
Intervention: Serum amyloid A level
Description: For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at -80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
Study NCT00562328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week.
Study NCT00562328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Weeks 2-5:~375 mg/m\^2 by IV once weekly
Study NCT00562328 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Week 1-6:~250 mcg subcutaneously three time as week
Study NCT04242745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.~A Beyid wristwatch was used. This spoke the time in Turkish, every hour on the hour. In this way, the old people were reminded to drink a glass of liquid each hour. The watch had an alarm capability, and could be taken on to sleep mode at night in order not to wake the old people.
Study NCT04242745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: The elderly in this group were trained using the For Your Health For Fluid training booklet and a projection device, and after training, all individuals were given a training booklet. The training was carried out individually in a room reserved for training and took an average of 25-30 minutes.
Study NCT00164723 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsule endoscopy
Description: Capsule endoscopy and colonoscopy
Study NCT01111669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
Study NCT01111669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (placebo)
Description: The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
Study NCT03848468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: excision of 3rd and 4th degree hemorrhoids
Study NCT03848468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Description: excision of 3rd and 4th degree hemorrhoids
Study NCT03869021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed surgical guide constructed
Description: A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
Study NCT03869021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: free hand surgery
Description: A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
Study NCT04415905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The participants in the group P are anesthetized with propofol
Study NCT04415905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The participants in the group S are anesthetized with sevoflurane.
Study NCT02310347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol
Study NCT02310347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01144806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
Study NCT01144806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Description: Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group